About John O'Malley
John O'Malley is chief medical officer at Matchpoint Therapeutics, which develops oral medicines for autoimmune and inflammatory diseases. He joined in October 2026 as Matchpoint advanced its lead program into clinical development. He previously was vice president, head of translational medicine and autoimmune disease program leader at CRISPR Therapeutics. There, he guided a clinical-stage CAR T-cell therapy and managed clinical translation work.
At Sanofi, he led amlitelimab’s clinical development across all indications, including mid- and late-stage trials. He also helped expand Dupixent into pediatric atopic dermatitis and prurigo nodularis as a senior clinical director. Earlier, he was an assistant professor of dermatology at Brigham and Women’s Hospital and studied human T-cell immunology. He treated skin lymphoma patients at Dana-Farber. He completed a postdoctoral dermatology fellowship at Harvard Medical School and served as chief dermatology resident at NewYork-Presbyterian Hospital and Columbia University Irving Medical Center. He earned an M.D. and Ph.D. from Indiana University and a B.S., summa cum laude, from Notre Dame.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name John O'Malley in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people John O'Malley works with at each company, as listed on that company's latest Form D.


